Pacira BioSciences, Inc. (PCRX): restructuring charge — Pacira BioSciences cuts 71 jobs (8% of workforce); decommissions 45-liter EXPAREL suite in San Diego

Pacira BioSciences, Inc.

Workforce reduction of 71 employees (~8% of total) from Technical Operations at San Diego Science Center Campus.
Pre-tax charges of $2.4M-$2.8M in Q3 2025 for employee termination benefits, plus $5.4M accelerated depreciation.
Decommissioning 45-liter manufacturing suite after bringing two larger 200+ liter suites online in San Diego and Swindon, UK.
Expects annual operating expense savings of ~$13 million from the reduction in force.
New large-scale suites produce bulk EXPAREL volumes approximately four-fold greater per batch, improving gross margins.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Pacira BioSciences, Inc. announced a restructuring with charges of approximately $2.4 million to $2.8 million affecting Science Center Campus in San Diego, California (71 employees or approximately 8% of the Company’s total workforce).

Type: restructuring
Charge: approximately $2.4 million to $2.8 million
Affected area: Science Center Campus in San Diego, California
Headcount: 71 employees or approximately 8% of the Company’s total workforce

Exact text from the filing

8% of the Company’s total workforce. The Company currently estimates that it will recognize pre-tax charges to its third quarter 2025 financial results of approximately $2.4 million to $2.8 million related to employee termination benefits, consisting of garden leave and severance, healthcare benefits, and, to a lesser extent, other one-time termination

View on SEC.gov

Browse all restructurings & charges →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-25-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.